Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 23, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Aptiv Solutions Improves Accuracy of Dose Escalation Studies with Launch of ADDPLAN® DF 3.0
Friday, May 16, 2014
ADDPLAN® DF 3.0 incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials.

Da Volterra's DAV132 Shown As Promising Candidate for Preventing Severe C. Difficile Infections
Tuesday, May 13, 2014
The CL1001 clinical trial also demonstrated the adequate targeted delivery of DAV132 to the ileum and the colon and its adsorbing effects.

Cleanroom Services Partnership Brings Synergy for Customers
Thursday, May 01, 2014
Two award-winning laboratory service providers have joined forces to create greater synergy for customers.

Quotient Clinical Extends its Translational Pharmaceutics™ Platform
Friday, April 25, 2014
Company will employ its manufacturing capabilities to supply specialist oncology centers with drug products.

New Approach to Temperature Control in Cell Therapy Clinical Trial
Wednesday, April 23, 2014
CoolCell® cell freezing device and CoolBox™ ice-free cooling workstations chosen to support handling and processing of investigational cell therapy product in landmark clinical research trial.

Critical Pharmaceuticals, The University of Nottingham and NUH Starts First Phase I Clinical Trial
Wednesday, April 16, 2014
Phase I clinical trial on a nano-enabled intranasal teriparatide for the treatment of osteoporosis.

ERT Introduces GE Healthcare’s QT Guard Plus™ Analysis System
Friday, April 11, 2014
Novel approach may help to prevent false positive cardiac safety findings in new drug development.

Vetter Launches New Clinical Syringe Packages
Friday, April 11, 2014
Earlier syringe development may cut time-to-market, increase clinical trial appeal.

Immunovaccine's DepoVax™ Technology Underpins New Experimental Therapy for Cancers
Wednesday, April 09, 2014
IMV vaccine adjuvant technology of choice for Dana-Farber's HPV-related cancer clinical trial.

<< 1 2 3 4 5 6 7 >>
Showing Results 11 - 20 of 294
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv